Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study.

BACKGROUND & OBJECTIVE Extensively drug-resistant tuberculosis (XDR-TB) is a difficult-to-treat form of multidrug-resistant tuberculosis (MDR-TB). High rates of XDR-TB have been reported from India. We sought to ascertain the prevalence of XDR-TB among patients with MDR-TB treated at a tertiary care centre in New Delhi, India. METHODS Case records of patients treated for MDR-TB at the All India Institute of Medical Sciences hospital, New Delhi, between 1997 and 2003 were retrospectively reviewed. All patients underwent a pretreatment drug-susceptibility testing (DST) to first- as well as second-line drugs. XDR-TB was defined as TB caused by bacilli showing resistance to rifampicin and isoniazid in addition to any fluoroquinolone and to at least one of the three following injectable drugs: capreomycin, kanamycin, and amikacin. RESULTS A total of 211 laboratory-confirmed cases of MDR-TB were reviewed. The mean age of the patients was 33 +/- 12 yr. Fifty one (24%) patients were females. All patients were sero-negative for human immunodeficiency virus infection. Five of the 211 MDR-TB patients had XDR-TB. The prevalence of XDR-TB was 2.4 per cent among MDR-TB patients. INTERPRETATION & CONCLUSION Our results showed that XDR-TB was rare among patients with MDR-TB treated between 1997 and 2003 at our centre. Unreported selection bias might have been responsible for the high prevalence of XDR-TB reported in previous hospital-based studies from India.

[1]  Sarman Singh,et al.  High rate of extensively drug-resistant tuberculosis in Indian AIDS patients , 2007, AIDS.

[2]  Amita Jain,et al.  Extensively Drug-Resistant Mycobacterium tuberculosis, India , 2007, Emerging infectious diseases.

[3]  N. S. Mohan,et al.  Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. , 2007, The Indian journal of tuberculosis.

[4]  Neel R Gandhi,et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.

[5]  R. Venkatesan,et al.  Prevalence of acquired MDR-TB and HIV co-infection. , 2002, The Indian journal of chest diseases & allied sciences.

[6]  D. Wilkinson.  Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) , 1998 .

[7]  S. Weis,et al.  A survey of drug‐resistant Mycobacterium tuberculosis and its relationship to HIV infection , 1998, AIDS.

[8]  G. Peersman,et al.  A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection. , 1998 .

[9]  S. Asch,et al.  Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis. , 1996, American journal of respiratory and critical care medicine.

[10]  J. T. Crawford,et al.  An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. , 1992, The New England journal of medicine.

[11]  L. Tanoue.  Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis , 2009 .

[12]  C. Dye,et al.  Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) , 1998 .

[13]  P HAUDUROY,et al.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. , 1963, Bulletin of the World Health Organization.